Albany, NY -- (SBWIRE) -- 08/03/2015 -- The Report Investigation Report on China Quetiapine Market, 2010-2019 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants.

Browse Complete Report with Toc: http://www.marketresearchreports.biz/analysis/302705

WHO estimated that the lifetime prevalence of schizophrenia is about 3.8%-8.4% in the world. According to the statistics published by National Center for Mental Health in 2014, the number of people with mental disorders is above 100 million. Suppose the mainland population was 1368 million, the number of people with schizophrenia shall be about 17.8 million. Symptoms of schizophrenia begin earlier in men than in women and are more common to see in men than in women. The risk of dying young in schizophrenia patients is 2 to 2.5 times that in common people. This is the result of increased physical health problems like cardiovascular, metabolic and epidemic diseases. Take diabetes for example, its incidence among schizophrenia patients is 2-3 times that in common people.

Developed by AstraZeneca plc., quetiapine (under the trade name of Seroquel) is an important drug for the treatment of schizophrenia. Approved by CFDA to treat schizophrenia in 2000, quetiapine was listed in the Catalogue of Drugs for the Basic National Medical Insurance in 2014. Currently, local manufacturers of quetiapine are Hunan Dongting Pharmaceutical Co., Ltd and Suzhou Pharmaceutical Group Co., Ltd. No.1 Pharmaceutical Factory, the former owning relevant patent for quetiapine compound according to CFDA.

Download The sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/302705

Quetiapine develops fast after entering China, sales value reaching CNY 116 million in 2013 and CNY 131 million in 2014 with a year-on-year growth of 12.93% and CAGR reaching 9.72% during the period of 2010-2014. With accelerating pace of life and increased life pressure, the incidence of mental disorder keeps going up, which fosters the vast demand for quetiapine in China. Currenly, Hunan Dongting Pharmaceutical Co., Ltd, Suzhou Pharmaceutical Group Co., Ltd. No.1 Pharmaceutical Factory and AstraZeneca plc. occupy the majority of market share, among which AstraZeneca plc. had the largest share of 78.50% for sales value in 2014. As local enterprises have patented quetiapine compound and sold it at a relatively low price, their market share is expected to expand in the next few years.

Browse More Reports Of Therapeutic Area Reports: http://www.marketresearchreports.biz/category/37

Readers can get at least the following information from this report:
market size of quetiapine in China
retail price of quetiapine in China
market outlook of quetiapine in China
The author suggests the following groups of people purchase this report:
manufacturers of antipsychotics
investors/ research institutions interested in Chinese medicine market
any interest in the medicine market, please contact CRI for customized survey service

About MarketResearchReports.biz
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

To View The Top Related News: http://www.marketresearchreports.biz/articles

Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/